CDKN2A and astrocytoma (excluding glioblastoma): Multiple studies have identified the homozygous deletion of CDKN2A/B as a marker of poor prognosis in patients with IDH-mutant astrocytomas, and a correlation with shorter survival has been confirmed in several studies (40, 41).